ArticleNature communications2022
Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 104 citations in OpenAlex.
- Rare-Earth Nanomaterials for Advanced Theranostics of Atherosclerosis.Chemical & biomedical imaging · 2026Review
- Sequence-regulated, lung-targeting heteropolypeptide nanoparticles via in situ erythrocyte hitchhiking.Nature communications · 2026Article
- Bioinspired porous metal-amino acid nanozymes enable multi-pathway treatment of atherosclerosis through anti-oxidation and pro-efferocytosis.Nature communications · 2026Article
- Biomimetic Ru-Mn Nanozyme with Cascade Catalytic Activity Attenuates Secondary Brain Injury in Intracerebral Hemorrhage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nature-inspired confined cascade enzyme nanoreactors for targeted atherosclerosis therapy.Signal transduction and targeted therapy · 2026Article
- Targeting engineered cell membrane camouflaged gallic acid-cerium nanozyme for intercepting the inflammation-free radical vicious cycle in atherosclerosis.Journal of nanobiotechnology · 2026Article
- Advances in nanomaterials for the diagnosis and treatment of ischemic heart disease.Discover nano · 2026Review
- Complementary antioxidant strategy for diabetic wound healing: myricetin and ceria nanozymes for enhanced reactive oxygen species management.Regenerative biomaterials · 2026Article
- Recent Advances in Nanodelivery Systems Based on Extracellular and Intracellular Reprogramming Strategies for Enhanced Therapy of Atherosclerosis.International journal of nanomedicine · 2026Review
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges.International journal of nanomedicine · 2026Review
- Mild photothermal-mediated neuroimmunomodulatory composite hydrogel ameliorates bone healing microenvironment for enhanced osteoporotic bone defect regeneration.Materials today. Bio · 2025Article
- Plaque-Targeted Delivery of Fluoride-Free MXene Nanozyme for Alleviating Atherosclerosis via Sonocatalytic Therapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Microenvironment-responsive multifunctional enzyme-linked hydrogel for diabetic bone defect regeneration.Nature communications · 2025Article
- Nanoparticle Drug Delivery Systems for Atherosclerosis: Precision Targeting, Inflammatory Modulation, and Plaque Stabilization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Platelet Membrane Biomimetic Chemiluminescent Nanoparticles for Targeted Therapy of Atherosclerosis.ACS applied materials & interfaces · 2025Article
- Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy.Science advances · 2025Article
- Nanomedicine in cardiovascular and cerebrovascular diseases: targeted nanozyme therapies and their clinical potential and current challenges.Journal of nanobiotechnology · 2025Review
- Intelligent nanozymes: Biomimetic design, mechanisms and biomedical applications.Fundamental research · 2025Review
- Oleanolic acid-based nanoparticles for the treatment of ulcerative colitis.Nanomedicine (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering that intravascular reactive oxygen species (ROS) and inflammation are two characteristic features of the atherosclerotic microenvironment, developing an appropriate strategy to treat atherosclerosis by synergistically regulating ROS and inflammation has attracted widespread attention. Herein, a special molecule, zoledronic acid, containing imidazole and bisphosphonate groups, was selected for the first time to assist the assembly of cerium ions and produce functionalized ceria-zoledronic acid nanocomposites (CZ NCs). It not only serves as a new carrier for different kinds of drugs (e.g. probucol, PB) but also exerts an efficient multienzyme activity to achieve collaborative therapy. More importantly, platelet membrane-coated biomimetic nanoplatform (PCZ@PB NCs) specifically accumulate at inflammatory atherosclerotic lesions, synergistically regulate ROS levels and inflammation, and efficiently inhibit foam cell formation. This novel assembly method can also be applied in the treatment of many other diseases associated with oxidative stress and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.